Course: Diagnosis and Management of Nonalcoholic Fatty Liver Disease
CME Credits: 1.00
Released: 2023-10-16
NAFLD is characterized by hepatic steatosis associated with metabolic abnormalities such as insulin resistance, dyslipidemia, obesity, and hypertension. Prevalence of NAFLD in US adults approaches 40%, with high-risk fibrosis more than doubling between 2000 and 2016 (National Health and Nutrition Examination Survey). Less than 5% of patients with NAFLD are aware of their condition, and 12% to 14% also have NASH, which can progress to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Diagnostic screening and initial treatment for NAFLD can often be carried out in primary care settings.
To identify the key insights or developments described in this article
View Full Course